NASDAQ: RVPH - Reviva Pharmaceuticals Holdings, Inc.

Altı ay boyunca karlılık: -24.31%
Temettü getirisi: 0.00%
Sektör: Healthcare

Promosyon programı Reviva Pharmaceuticals Holdings, Inc.


Şirket hakkında Reviva Pharmaceuticals Holdings, Inc.

Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases.

daha fazla ayrıntı
The company's lead product candidate is brilaroxazine (RP5063), which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attention–deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company is based in Cupertino, California.

IPO date 2018-10-18
ISIN US76152G1004
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://revivapharma.com
Цена ао 1.09
Günlük fiyat değişimi: 0% (1.09)
Haftalık fiyat değişimi: +4.81% (1.04)
Aylık fiyat değişimi: -18.66% (1.34)
3 ayda fiyat değişimi: -39.44% (1.8)
Altı ayda fiyat değişimi: -24.31% (1.44)
Yıllık fiyat değişimi: -71.16% (3.78)
3 yılda fiyat değişimi: -46.31% (2.03)
5 yılda fiyat değişimi: -89.68% (10.56)
Yılbaşından bu yana fiyat değişimi: -39.78% (1.81)

Hafife alma

İsim Anlam Seviye
P/S 0 0
P/BV 24.9 1
P/E 0 0
EV/EBITDA -1.83 0
Toplam: 2.63

Yeterlik

İsim Anlam Seviye
ROA, % -165.65 0
ROE, % -686.53 0
Toplam: 0

Temettüler

İsim Anlam Seviye
Div yield, % 0 0
DSI 0 0
Toplam: 0

Görev

İsim Anlam Seviye
Debt/EBITDA 0 10
Toplam: 9.8

Büyüme dürtüsü

İsim Anlam Seviye
karlılık Revenue, % 0 0
karlılık Ebitda, % 10506286070.21 10
karlılık EPS, % 539836144.2 10
Toplam: 8

Kurumlar Hacim Paylaşmak, %
Vanguard Group Inc 615932 2.72
Armistice Capital, LLC 600000 2.65
Millennium Management LLC 423132 1.87
Geode Capital Management, LLC 171192 0.76
Colony Group LLC 171000 0.75
Group One Trading, L.P. 129301 0.57
EMC Capital Management 123915 0.55
Blackrock Inc. 88690 0.39
GSA Capital Partners LLP 70181 0.31
Belvedere Trading LLC 49501 0.22

ETFPaylaşmak, %Yıllık karlılık, %Temettüler, %
iShares Micro-Cap ETF 0.00604 17.09 1.54048
0.0117.091.54



Süpervizör İş unvanı Ödeme Doğum yılı
Dr. Laxminarayan Bhat Ph.D. Founder, CEO, President & Director 560k 1965 (60 yıllar)
Mr. Narayan Prabhu Chief Financial Officer 412.5k 1972 (53 yıl)

Adres: United States, Cupertino. CA, 19925 Stevens Creek Boulevard - Google haritalarda aç, Yandex haritalarını aç
Web sitesi: https://revivapharma.com